Patents by Inventor Deyi Zhang
Deyi Zhang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11127535Abstract: A ferroelectric enhanced solar cell, including a conductive substrate, and a hole blocking layer, a mesoporous nanocrystalline layer, a mesoporous spacer layer and a mesoporous back electrode sequentially deposited in that order on the conductive substrate. The mesopores of at least one of the mesoporous nanocrystalline layer, the mesoporous spacer layer and the mesoporous back electrode are filled with a photoactive material. At least one of the hole blocking layer, the mesoporous nanocrystalline layer and the mesoporous spacer layer includes a ferroelectric material or a ferroelectric nanocomposite.Type: GrantFiled: October 17, 2019Date of Patent: September 21, 2021Assignee: HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGYInventors: Hongwei Han, Anyi Mei, Shuang Liu, Xiaolei Li, Deyi Zhang
-
Patent number: 10775182Abstract: A load and route assignment system is provided and generally includes a computing device and a database. The database may store historical inbound load data and historical outbound load data related to previous inbound and outbound loads. The computing device can obtain and aggregate the historical inbound and outbound load data from the database, and determine an optimal path based on the aggregated historical data. The optimal path, along with load attribute data, may be stored in the database as a tour template for future load executions. The computing device may use the tour templates to determine future load assignments to vehicles. The computing device may also obtain real-time load requests, and match them to one or more of a plurality of tour templates. The computing device may assign the matched real-time load requests to a vehicle for execution in accordance with the corresponding load and tour template.Type: GrantFiled: September 12, 2018Date of Patent: September 15, 2020Assignee: Walmart Apollo, LLCInventors: Mingang Fu, Pushkar Raj Pande, Amritayan Nayak, Deepak Deshpande, Madhavan Kandhadai Vasantham, Syed Aman, Deyi Zhang
-
Publication number: 20200080854Abstract: A load and route assignment system is provided and generally includes a computing device and a database. The database may store historical inbound load data and historical outbound load data related to previous inbound and outbound loads. The computing device can obtain and aggregate the historical inbound and outbound load data from the database, and determine an optimal path based on the aggregated historical data. The optimal path, along with load attribute data, may be stored in the database as a tour template for future load executions. The computing device may use the tour templates to determine future load assignments to vehicles. The computing device may also obtain real-time load requests, and match them to one or more of a plurality of tour templates. The computing device may assign the matched real-time load requests to a vehicle for execution in accordance with the corresponding load and tour template.Type: ApplicationFiled: September 12, 2018Publication date: March 12, 2020Inventors: Mingang Fu, Pushkar Raj Pande, Amritayan Nayak, Deepak Deshpande, Madhavan Kandhadai Vasantham, Syed Aman, Deyi Zhang
-
Publication number: 20200082335Abstract: A load and route assignment system is provided and generally includes a computing device and a database. The database may store historical inbound load data and historical outbound load data related to previous inbound and outbound loads. The computing device can obtain and aggregate the historical inbound and outbound load data from the database, and determine an optimal path based on the aggregated historical data. The optimal path, along with load attribute data, may be stored in the database as a tour template for future load executions. The computing device may use the tour templates to determine future load assignments to vehicles. The computing device may also obtain real-time load requests, and match them to one or more of a plurality of tour templates. The computing device may assign the matched real-time load requests to a vehicle for execution in accordance with the corresponding load and tour template.Type: ApplicationFiled: September 12, 2018Publication date: March 12, 2020Inventors: Mingang Fu, Pushkar Raj Pande, Amritayan Nayak, Deepak Deshpande, Madhavan Kandhadai Vasantham, Syed Aman, Deyi Zhang
-
Publication number: 20200051753Abstract: A ferroelectric enhanced solar cell, including a conductive substrate, and a hole blocking layer, a mesoporous nanocrystalline layer, a mesoporous spacer layer and a mesoporous back electrode sequentially deposited in that order on the conductive substrate. The mesopores of at least one of the mesoporous nanocrystalline layer, the mesoporous spacer layer and the mesoporous back electrode are filled with a photoactive material. At least one of the hole blocking layer, the mesoporous nanocrystalline layer and the mesoporous spacer layer includes a ferroelectric material or a ferroelectric nanocomposite.Type: ApplicationFiled: October 17, 2019Publication date: February 13, 2020Inventors: Hongwei HAN, Anyi MEI, Shuang LIU, Xiaolei LI, Deyi ZHANG
-
Patent number: 10023593Abstract: An ALK kinase inhibitor compound as represented by Formula I, pharmaceutical composition containing the compound, and preparation method and use thereof in the preparation of drugs serving as an ALK inhibitor for treating cancer.Type: GrantFiled: May 29, 2015Date of Patent: July 17, 2018Assignee: Beijing Pearl Biotechnology Limited Liability CompanyInventors: Jiaqiang Dong, Boyu Zhong, Hongbin Yuan, Chuan Shih, Shaosong Chu, Deyi Zhang, Ruihao Zhang
-
Patent number: 9840477Abstract: The present disclosure relates to novel cyclopropanecarboxamido-substituted aromatic compounds that inhibit protein kinases and their use in anti-tumor area. In particular, the disclosure relates to novel tyrosine-kinase inhibitors and Raf-kinase inhibitors as anti-tumor agents, their preparation, pharmaceutical composition, and their use in the treatment of cancer.Type: GrantFiled: June 6, 2016Date of Patent: December 12, 2017Assignee: CB THERAPEUTICS INC.Inventor: Deyi Zhang
-
Publication number: 20170247392Abstract: An ALK kinase inhibitor compound as represented by Formula I, pharmaceutical composition containing the compound, and preparation method and use thereof in the preparation of drugs serving as an ALK inhibitor for treating cancer.Type: ApplicationFiled: May 29, 2015Publication date: August 31, 2017Inventors: Jiaqiang DONG, Boyu ZHONG, Hongbin YUAN, Chuan SHIH, Shaosong CHU, Deyi ZHANG, Ruihao ZHANG
-
Publication number: 20170044136Abstract: The present invention relates to compounds of formula I: or pharmaceutically acceptable acid addition salts thereof, where; R1 is C1-C6 alkyl, substituted C1-C6 alkyl, C3-C7 cycloalkyl, substituted C3-C7 cycloalkyl, C3-C7 cycloalkyl-C1-C3 alkyl, substituted C3-C7 cycloalkyl-C1-C3 alkyl, phenyl, substituted phenyl, heterocycle, or substituted heterocycle; R2 is hydrogen, C1-C3 alkyl, C3-C6 cycloalkyl-C1-C3 alkyl, or a group of formula II R3 is hydrogen or C1-C3 alkyl; R4 is hydrogen, halo, or C1-C3 alkyl; R5 is hydrogen or C1-C3 alkyl; R6 is hydrogen or C1-C6 alkyl; and n is an integer from 1 to 6 inclusively. The compounds of the present invention are useful for activating 5-HT1F receptors, inhibiting neuronal protein extravasation, and for the treatment or prevention of migraine in a mammal. The present invention also relates to a process for the synthesis of intermediates in the synthesis of compounds of Formula I.Type: ApplicationFiled: April 6, 2016Publication date: February 16, 2017Inventors: Michael Philip Cohen, Daniel Timothy Kohlman, Sidney Xi Liang, Frantz Victor, Yao-Chang Xu, Bai-Ping Ying, DeAnna Piatt Zacherl, Deyi Zhang
-
Publication number: 20160280664Abstract: The present disclosure relates to novel cyclopropanecarboxamido-substituted aromatic compounds that inhibit protein kinases and their use in anti-tumor area. In particular, the disclosure relates to novel tyrosine-kinase inhibitors and Raf-kinase inhibitors as anti-tumor agents, their preparation, pharmaceutical composition, and their use in the treatment of cancer.Type: ApplicationFiled: June 6, 2016Publication date: September 29, 2016Inventor: Deyi Zhang
-
Patent number: 9359338Abstract: Provided are cyclopropanecarboxamido-substituted aromatic compounds that inhibit protein kinases and their use in anti-tumor area. In particular, tyrosine-kinase inhibitors and Raf-kinase inhibitors as anti-tumor agents, their preparation, pharmaceutical composition, and their use in the treatment of cancer are also provided.Type: GrantFiled: June 24, 2013Date of Patent: June 7, 2016Assignee: CROWN BIOSCIENCE INC. (Taiwan)Inventors: Deyi Zhang, Ruihao Zhang, Boyu Zhong, Chuan Shih
-
Publication number: 20150376178Abstract: The present invention relates to compounds of formula I: or pharmaceutically acceptable acid addition salts thereof, where; R1 is C1-C6 alkyl, substituted C1-C6 alkyl, C3-C7 cycloalkyl, substituted C3-C7 cycloalkyl, C3-C7 cycloalkyl-C1-C3 alkyl, substituted C3-C7 cycloalkyl-C1-C3 alkyl, phenyl, substituted phenyl, heterocycle, or substituted heterocycle; R2 is hydrogen, C1-C3 alkyl, C3-C6 cycloalkyl-C1-C3 alkyl, or a group of formula II R3 is hydrogen or C1-C3 alkyl; R4 is hydrogen, halo, or C1-C3 alkyl; R5 is hydrogen or C1-C3 alkyl; R6 is hydrogen or C1-C6 alkyl; and n is an integer from 1 to 6 inclusively. The compounds of the present invention are useful for activating 5-HT1F receptors, inhibiting neuronal protein extravasation, and for the treatment or prevention of migraine in a mammal. The present invention also relates to a process for the synthesis of intermediates in the synthesis of compounds of Formula I.Type: ApplicationFiled: June 5, 2014Publication date: December 31, 2015Inventors: Michael Philip Cohen, Daniel Timothy Kohlman, Sidney Xi Liang, Frantz Victor, Yao-Chang Xu, Bai-Ping Ying, DeAnna Piatt Zacherl, Deyi Zhang
-
Publication number: 20150197511Abstract: Provided are cyclopropanecarboxamido-substituted aromatic compounds that inhibit protein kinases and their use in anti-tumor area. In particular, tyrosine-kinase inhibitors and Raf-kinase inhibitors as anti-tumor agents, their preparation, pharmaceutical composition, and their use in the treatment of cancer are also provided.Type: ApplicationFiled: June 24, 2013Publication date: July 16, 2015Inventors: Deyi Zhang, Ruihao Zhang, Boyu Zhong, Chuan Shih
-
Patent number: 8748459Abstract: The present invention relates to compounds of formula I: or pharmaceutically acceptable acid addition salts thereof, where; R1 is C1-C6 alkyl, substituted C1-C6 alkyl, C3-C7 cycloalkyl, substituted C3-C7 cycloalkyl, C3-C7 cycloalkyl-C1-C3 alkyl, substituted C3-C7 cycloalkyl-C1-C3 alkyl, phenyl, substituted phenyl, heterocycle, or substituted heterocycle; R2 is hydrogen, C1-C3 alkyl, C3-C6 cycloalkyl-C1-C3 alkyl, or a group of formula II R3 is hydrogen or C1-C3 alkyl; R4 is hydrogen, halo, or C1-C3 alkyl; R5 is hydrogen or C1-C3 alkyl; R6 is hydrogen or C1-C6 alkyl; and n is an integer from 1 to 6 inclusively. The compounds of the present invention are useful for activating 5-HTlF receptors, inhibiting neuronal protein extravasation, and for the treatment or prevention of migraine in a mammal. The present invention also relates to a process for the synthesis of intermediates in the synthesis of compounds of Formula I.Type: GrantFiled: February 1, 2012Date of Patent: June 10, 2014Assignee: Eli Lilly and CompanyInventors: Michael Philip Cohen, Daniel Timothy Kohlman, Sidney Xi Liang, Frantz Victor, Yao-Chang Xu, Bai-Ping Ying, DeAnna Piatt Zacherl, Deyi Zhang
-
Patent number: 8580780Abstract: The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula I as selective 5-HT2C receptor agonists for the treatment of 5-HT2C associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety: where: R6 is —S—R14; and other substituents are as defined in the specification.Type: GrantFiled: July 28, 2011Date of Patent: November 12, 2013Assignee: Eli Lilly and CompanyInventors: John Gordon Allen, Karin Briner, Christopher Stanley Galka, Maria Angeles Martinez-Grau, Matthew Robert Reinhard, Michael John Rodriguez, Roger Ryan Rothhaar, Michael Wade Tidwell, Frantz Victor, Deyi Zhang, Steven Armen Boyd, Arundhati S. Deo, Wai-Man Lee, Christopher Stephen Siedem, Ajay Singh
-
Publication number: 20120329820Abstract: The present invention relates to compounds of formula I: or pharmaceutically acceptable acid addition salts thereof, where; R1 is C1-C6 alkyl, substituted C1-C6 alkyl, C3-C7 cycloalkyl, substituted C3-C7 cycloalkyl, C3-C7 cycloalkyl-C1-C3 alkyl, substituted C3-C7 cycloalkyl-C1-C3 alkyl, phenyl, substituted phenyl, heterocycle, or substituted heterocycle; R2 is hydrogen, C1-C3 alkyl, C3-C6 cycloalkyl-C1-C3 alkyl, or a group of formula II R3 is hydrogen or C1-C3 alkyl; R4 is hydrogen, halo, or C1-C3 alkyl; R5 is hydrogen or C1-C3 alkyl; R6 is hydrogen or C1-C6 alkyl; and n is an integer from 1 to 6 inclusively. The compounds of the present invention are useful for activating 5-HT1F receptors, inhibiting neuronal protein extravasation, and for the treatment or prevention of migraine in a mammal. The present invention also relates to a process for the synthesis of intermediates in the synthesis of compounds of Formula I.Type: ApplicationFiled: February 1, 2012Publication date: December 27, 2012Applicant: Eli Lilly and CompanyInventors: Michael P. Cohen, Daniel T. Kohlman, Sidney X. Liang, Frantz Victor, Yao-Chang Xu, Bai-Ping Ying, Deanna P. Zacherl, Deyi Zhang
-
Publication number: 20120028961Abstract: The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula I as selective 5-HT2C receptor agonists for the treatment of 5-HT2C associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety: where: R6 is —S—R14; and other substituents are as defined in the specification.Type: ApplicationFiled: July 28, 2011Publication date: February 2, 2012Applicant: ELI LILLY AND COMPANYInventors: JOHN GORDON ALLEN, Karin Briner, Michael Philip Cohen, Christopher Stanley Galka, Sarah Lynne Hellman, Maria Angeles Martinez-Grau, Matthew Robert Reinhard, Michael John Rodriguez, Roger Ryan Rothhaar, Michael Wade Tidwell, Frantz Victor, Andrew Caerwyn Williams, Deyi Zhang, Steven Armen Boyd, Richard Gerard Conway, Arundhati S. Deo, Wai-Man Lee, Christopher Stephen Siedem, Ajay Singh, Michael Philip MAZANETZ
-
Patent number: 8022062Abstract: The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula I as selective 5-HT2C receptor agonists for the treatment of 5-HT2C associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety: where: R6 is —C?C—R10, —O—R12, —S—R14, or —NR24R25; and other substituents are as defined in the specification.Type: GrantFiled: February 18, 2005Date of Patent: September 20, 2011Assignee: Eli Lilly and CompanyInventors: John Gordon Allen, Karin Briner, Michael Philip Cohen, Christopher Stanley Galka, Sarah Lynne Hellman, Maria Angeles Martinez-Grau, Matthew Robert Reinhard, Michael John Rodriguez, Roger Ryan Rothhaar, Michael Wade Tidwell, Frantz Victor, Andrew Caerwyn Williams, Deyi Zhang, Michael Philip Mazanetz
-
Patent number: 7981882Abstract: The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula I as selective 5-HT2C receptor agonists for the treatment of 5-HT2C associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety: Formula (I) where: R6 is selected from the group consisting of (a, b, c, d, e) and other substituents are as defined in the specification.Type: GrantFiled: September 1, 2006Date of Patent: July 19, 2011Assignee: Eli Lilly and CompanyInventors: Karin Briner, Anne Marie Camp, Alan Cornell, Michael Philip Mazanetz, Roger Ryan Rothhaar, Frantz Victor, Andrew Caerwyn Williams, Deyi Zhang
-
Publication number: 20110034511Abstract: The present invention relates to compounds of formula I: or a pharmaceutically acceptable acid addition salt thereof, wherein X is C(R3c)? or N?; R1 is C2-C6 alkyl, substituted C2-C6 alkyl, C3-C7 cycloalkyl, substituted C3-C7 cycloalkyl, phenyl, substituted phenyl, heterocycle, or substituted heterocycle; R2 is hydrogen, C1-C3 n-alkyl, C3-C6 cycloalkyl-C1-C3 alkyl, or a group of formula II provided that when R1 is C2-C6 alkyl or substituted C2-C6 alkyl, R2 is hydrogen or methyl; R3a, R3b and, when X is —C(R3c)?, R3c, are each independently hydrogen, fluoro, or methyl, provided that no more than one of R3a, R3b, and R3c may be other than hydrogen; R4 is hydrogen or C1-C3 alkyl; R5 is hydrogen, C1-C3 alkyl, or C3-C6 cycloalkylcarbonyl, provided that when R3a is other than hydrogen, R5 is hydrogen; R6 is hydrogen or C1-C6 alkyl; and n is an integer from 1 to 6 inclusively.Type: ApplicationFiled: September 28, 2010Publication date: February 10, 2011Applicant: Eli Lilly and CompanyInventors: Maria-Jesus Blanco-Pillado, Michael Philip Cohen, Sandra Ann Filla, Kevin John Hudziak, Daniel Timothy Kohlman, Dana Rae Benesh, Frantz Victor, Yao-Chang Xu, Bai-Ping Ying, DeAnna Piatt Zacherl, Deyi Zhang, Brian Michael Mathes